One small pilot study involving upfront chemomobilization plus plerixafor plus G-CSF in patients with MM and NHL demonstrated efficacy with a twofold increase in CD34+ cell collection [89]. The gene discussed is CSF3; the disease is non-Hodgkin lymphoma.